サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1306045

医薬品有効成分 (API)：世界市場の展望・予測 (2023-2028年)

Active Pharmaceutical Ingredients (APIs) Market - Global Outlook & Forecast 2023-2028
出版日: | 発行: Arizton Advisory & Intelligence | ページ情報: 英文 373 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
医薬品有効成分 (API)：世界市場の展望・予測 (2023-2028年)
出版日: 2023年07月12日
発行: Arizton Advisory & Intelligence
ページ情報: 英文 373 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の医薬品有効成分 (API) の市場規模は2022年から2028年にかけて6.67％のCAGRで成長すると予測されています。

複雑な病気や疾患、病状を治療するための、より専門的な新薬に対するニーズの高まりから、新規APIへの需要が高まっています。新規APIは高度なバイオテクノロジーと高度な合成技術を用いて開発されます。安全性、有効性、費用対効果の向上など、既存の医薬品と比較していくつかの利点があることからも新規APIの需要が高まっています。

当レポートでは、世界の医薬品有効成分 (API) の市場を調査し、市場の定義と概要、市場機会・市場動向、市場影響因子の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 調査目的

第3章 調査プロセス

第4章 調査対象・調査範囲

第5章 レポートの前提・注記

第6章 市場概要

第7章 重要考察

第8章 イントロダクション

第9章 市場機会・市場動向

  • 医薬品API産業のデジタルトランスフォーメーション
  • バイオシミラーの採用の増加
  • 新規APIの需要

第10章 市場成長の実現因子

  • API製造における技術の進歩
  • ジェネリック医薬品の需要
  • 製薬産業の成長
  • APIアウトソーシング業務の増加

第11章 市場抑制要因

  • 厳しい政府規制
  • 低い利益率と高いAPI製造コスト
  • テストプロセスにおける分析上の課題

第12章 市場情勢

  • 市場概要
  • 市場規模・予測
  • 市場機会
  • ファイブフォース分析

第13章 分子タイプ

  • 市場のスナップショット・成長エンジン
  • 市場概要
  • 低分子/化学API
  • 高分子/生物学的API

第14章 治療領域

  • 市場のスナップショット・成長エンジン
  • 市場概要
  • 心血管
  • 腫瘍
  • 神経
  • 抗感染症薬
  • 内分泌
  • 呼吸器
  • その他

第15章 製造業者タイプ

  • 市場のスナップショット・成長エンジン
  • 市場概要
  • 自社用
  • 商用

第16章 ブランド

  • 市場のスナップショット・成長エンジン
  • 市場概要
  • 特許取得済み/革新的API
  • 汎用API

第17章 有効性

  • 市場のスナップショット・成長エンジン
  • 市場概要
  • 非薬理活性API
  • 高薬理活性API

第18章 地域

  • 市場のスナップショット・成長エンジン
  • 地域概要

第19章 北米

第20章 アジア太平洋

第21章 欧州

第22章 ラテンアメリカ

第23章 中東・アフリカ

第24章 競合情勢

  • 競合概要
  • 市場シェア分析

第25章 主要企業プロファイル

  • ABBVIE
  • BOEHRINGER INGELHEIM
  • BRISTOL-MYERS SQUIBB COMPANY
  • CIPLA
  • ELI LILLY AND COMPANY
  • GSK
  • MERCK KGAA
  • NOVARTIS
  • PFIZER
  • SANOFI
  • SUN PHARMACEUTICAL INDUSTRIES
  • VIATRIS

第26章 他の有力ベンダー

  • ABBOTT
  • ALBEMARLE CORPORATION
  • AMGEN
  • AUROBINDO PHARMA
  • BASF CORPORATION
  • BIOCON
  • DR. REDDY'S LABORATORIES
  • TEVA PHARMACEUTICAL INDUSTRIES
  • F. HOFFMANN-LA ROCHE
  • GLENMARK PHARMACEUTICALS
  • LUPIN
  • SHENZHEN HEPALINK PHARMACEUTICAL GROUP

第27章 レポート概要

  • 重要ポイント
  • 戦略的提言

第28章 定量的サマリー

第29章 付録

目次

The global active pharmaceutical ingredients (API) market is expected to grow at a CAGR of 6.67% from 2022 to 2028.

MARKET TRENDS & DRIVERS

Reshaping the Pharmaceutical API Industry with Digital Transformation

Digital Transformation has allowed the active pharmaceutical ingredients (API) market to reshape itself to optimize production, streamline processes and reduce costs. By embracing the digital revolution, API manufacturers and suppliers can leverage advances in automated workflows, AI-enabled production management, and increased predictive analytics capabilities for data-driven decision-making. Additionally, the cloud-based infrastructure allows API-focused stakeholders to store, manage and use their data. At the same time, the increasing affordability of automation and other digital technologies helps to create a more efficient and cost-effective API supply chain more easily. Together, these advancements have enabled the pharmaceutical API industry to become more agile, responsive, and cost-efficient - unlocking new possibilities for product innovation and providing customers with a better overall experience.

Rising Demand for Novel APIs

The rising demand for novel APIs is due to the increasing need for newer, more specialized drugs to treat complex diseases, illnesses, and medical conditions. Novel APIs are developed using advanced biotechnologies and advanced synthesis techniques to create more effective drugs that provide better treatment than existing drugs. The growing demand for novel APIs is that they present several advantages over existing drugs, including improved safety, efficacy, and cost-effectiveness. Moreover, they can be used to treat rare diseases that current drugs cannot treat and to produce new therapies for existing diseases.

Technological Advancements API Manufacturing

The technological advancements in manufacturing in the active pharmaceutical ingredients (API) market have helped improve API quality, increase production efficiency, reduce costs, and ensure environmental protection. New technologies for API manufacturing include continuous processing and computerization of operations, which enable large-scale, cost-effective, and efficient production. Automated machines, computer-controlled process description (CPD) systems, and digital manufacturing systems are now being used to increase the accuracy of API formulation, improve overall efficiency, and reduce manual labor requirements. In addition, new technological advancements such as micronization techniques, nanotechnology, and crystallization techniques greatly improve API quality while increasing overall production speeds. Finally, new waste management methods, such as liquid waste treatments, have also significantly improved API manufacturing processes, as well as standards of environmental protection.

Growing Importance & Demand for Generic Drugs

Over recent years, the growing importance and demand for generic drugs have increased tremendously. This is mainly due to the cost savings they offer, as generic drugs typically cost 30-80% less than other brand-name drugs. Moreover, generic drugs are often the only option for patients who cannot afford expensive brand-name drugs. As such, generic drugs have become increasingly popular among consumers seeking affordable healthcare solutions. Additionally, generic drugs have become more widely available due to government programs like Medicaid and Medicare. These government-sponsored programs help to make generic drugs more accessible to those who need them. Furthermore, the increased demand for generic drugs has led to yet another significant development in the pharmaceutical industry: the formation of API manufacturers. These companies specialize in the production of APIs that are designed explicitly for generic medications. Creating APIs specifically tailored to generics can provide a cost-effective alternative to more expensive original drugs. As a result, manufacturers in the active pharmaceutical ingredients (API) market have become an essential component of the generic drug supply chain.

SEGMENTATION INSIGHTS

INSIGHTS BY MOLECULE TYPE

The global active pharmaceutical ingredients (API) market by molecule type is classified as large and small. This differentiation not only considers the size of the molecule but also how the molecules are made, their behavior, drug delivery, and mode of delivery. A small molecule API refers to an organic compound with a size of about 1 nm, which assists in regulating biological processes. Small molecules may be orally delivered, and the body is most likely to consume them. They possess the characteristics of rapid infusibility due to their small size, which enables them to reach the intercellular site of action. Small molecules have long been the basis for drug development. They are easily digested or absorbed into the bloodstream.

Segmentation by Molecule Type

  • Small Molecule/ Chemical API
  • Large Molecule/ Biological API

INSIGHTS BY THERAPY AREA

The cardiovascular therapy area dominated the global active pharmaceutical ingredients (API) market, accounting for a share of over 19% in 2022. Cardiovascular APIs are manufactured by companies involved in drug manufacturing for cardiovascular diseases. Manufacturers producing hypertensive drugs for people with high blood pressure drive the market's growth. Cardiovascular disease is a major cause of death and disability worldwide and is a major medical research and development focus. Pharmaceutical interventions are an important part of treatment for cardiovascular conditions, particularly when managing risk factors such as high blood pressure, high cholesterol, and diabetes. APIs are used to create medicines targeting specific aspects of the condition to achieve effective cardiovascular therapy.

Segmentation by Therapy Area

  • Cardiovascular
  • Oncology
  • Neurology
  • Anti-infectives
  • Endocrinology
  • Pulmonology
  • Others

INSIGHTS BY MANUFACTURERS TYPE

Based on the type of manufacturing process that an API-producing company opts for, the active pharmaceutical ingredients (API) market is segmented into captive and merchant markets. The captive market includes APIs produced by manufacturers in-house for their own needs, while the merchant market for APIs includes APIs manufactured by third parties. There are a lot of benefits and shortcomings of producing APIs in-house. COVID-19 has fueled the need for producing APIs in-house rather than outsourcing due to disruptions in the supply chain in China.

Segmentation by Manufacturers Type

  • Captive
  • Merchant

INSIGHTS BY BRAND

The patented/ innovative APIs segment accounted for a higher global active pharmaceutical ingredients (API) market in 2022. The use of patented or innovative active pharmaceutical ingredients (API) has become increasingly important in the pharmaceutical industry in recent years. Patented API can give a pharmaceutical company a competitive advantage through its exclusive access to the API, enabling it to sell products at higher margins and have a greater market share. API innovation is a necessary component of the pharmaceutical industry since it advances the development of new and improved pharmaceutical products that can benefit patients

Segmentation by Brand

  • Patented/ Innovative API
  • Generic API

INSIGHTS BY POTENCY

Active pharmaceutical ingredients (APIs) are essential components in producing pharmaceutical products. They are the active components in medicines that are responsible for the desired therapeutic effect. In recent years, the potency of APIs has become increasingly important for producing safe and effective medicines. Non-potent active pharmaceutical ingredients (NAPIs) are substances used as active ingredients in pharmaceuticals but do not possess the same potency as their potent counterparts (APIs). NAPIs are typically combined with APIs to enhance the drugs' therapeutic effect or reduce their toxicity. Low-potency NAPIs are generally considered safe for human consumption and are used to provide minor therapeutic benefits. The global non-potent active pharmaceutical ingredients (API) market is expected to grow at a CAGR of over 6% during the forecast period.

Segmentation by Potency

  • Non-potent API
  • Highly Potent API

GEOGRAPHICAL ANALYSIS

North America is one of the largest global active pharmaceutical ingredients (API) markets, accounting for over 41% share in 2022. The region has seen a steady growth in the demand for APIs, driven primarily by the increasing prevalence of chronic diseases, the rising demand for generic drugs, and the rapid development of the pharmaceutical industry. The increasing number of chronic diseases in North America has been a major factor driving the demand for APIs. According to the Centers for Disease Control and Prevention (CDC), around half of the adults in the U.S. suffer from at least one chronic disease. This has led to an increase in the use of prescription drugs, which in turn has led to an increase in the demand for APIs.

Segmentation by Geography

  • North America
    • The U.S.
    • Canada
  • APAC
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Indonesia
    • Singapore
  • Europe
    • Germany
    • The U.K.
    • Russia
    • France
    • Spain
    • Italy
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • South Africa

COMPETITIVE LANDSCAPE

The active pharmaceutical ingredients (API) market is concentrated, competitive, and characterized by numerous global and domestic vendors across geographies. AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb Company, Cipla, Eli Lilly and Company, GSK, Merck KGaA, Novartis, Pfizer, Sanofi, Sun Pharmaceuticals, and Viatris are the prominent vendors in the global active pharmaceutical ingredients (API) market. These companies are always at the forefront of delivering high-quality APIs for domestic and international pharmaceutical manufacturers. They also invest in considerable R&D activities to offer a competitive product line.

Key Company Profiles

  • AbbVie
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Cipla
  • Eli Lilly and Company
  • GSK
  • Merck KGaA
  • Novartis
  • Pfizer
  • Sanofi
  • Sun Pharmaceutical Industries
  • Viatris

Other Prominent Vendors

  • Abbott
  • Albemarle Corporation
  • Amgen
  • Aurobindo Pharma
  • BASF Corporation
  • Biocon
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceuticals Industries
  • F. Hoffmann-La Roche
  • GLENMARK PHARMACEUTICALS LTD.
  • Lupin
  • Shenzhen Hepalink Pharmaceutical Group

KEY QUESTIONS ANSWERED:

  • 1. How big is the active pharmaceutical ingredients (API) market?
  • 2. What is the growth rate of the global active pharmaceutical ingredients (API) market?
  • 3. What are the growing trends in the active pharmaceutical ingredients (API) market?
  • 4. Which region holds the most significant global active pharmaceutical ingredients (API) market share?
  • 5. Who are the key players in the global active pharmaceutical ingredients (API) market?

TABLE OF CONTENTS

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

  • 4.1 MARKET DEFINITION
    • 4.1.1 INCLUSIONS
    • 4.1.2 EXCLUSIONS
    • 4.1.3 MARKET ESTIMATION CAVEATS
  • 4.2 BASE YEAR
  • 4.3 SCOPE OF THE STUDY
    • 4.3.1 MARKET SEGMENTATION BY MOLECULE TYPE
    • 4.3.2 MARKET SEGMENTATION BY THERAPY AREA
    • 4.3.3 MARKET SEGMENTATION BY MANUFACTURER TYPE
    • 4.3.4 MARKET SEGMENTATION BY BRAND
    • 4.3.5 MARKET SEGMENTATION BY POTENCY
    • 4.3.6 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

  • 5.1 KEY CAVEATS
  • 5.2 CURRENCY CONVERSION
  • 5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 PREMIUM INSIGHTS

  • 7.1 OVERVIEW
    • 7.1.1 GEOGRAPHY INSIGHTS
    • 7.1.2 MOLECULE TYPE SEGMENTATION INSIGHTS
    • 7.1.3 THERAPY AREA SEGMENTATION INSIGHTS
    • 7.1.4 MANUFACTURER TYPE SEGMENTATION INSIGHTS
    • 7.1.5 BRAND SEGMENTATION INSIGHTS
    • 7.1.6 POTENCY SEGMENTATION INSIGHTS

8 INTRODUCTION

  • 8.1 OVERVIEW
    • 8.1.1 IMPACT OF COVID-19

9 MARKET OPPORTUNITIES & TRENDS

  • 9.1 DIGITAL TRANSFORMATION OF PHARMACEUTICAL API INDUSTRY
  • 9.2 INCREASED ADOPTION OF BIOSIMILARS
  • 9.3 DEMAND FOR NOVEL APIS

10 MARKET GROWTH ENABLERS

  • 10.1 TECHNOLOGICAL ADVANCES IN API MANUFACTURING
  • 10.2 DEMAND FOR GENERIC DRUGS
  • 10.3 GROWTH OF PHARMACEUTICAL INDUSTRY
  • 10.4 INCREASED API OUTSOURCING OPERATIONS

11 MARKET RESTRAINTS

  • 11.1 STRINGENT GOVERNMENT REGULATIONS
  • 11.2 LOW PROFIT MARGINS & HIGH API-MANUFACTURING COSTS
  • 11.3 ANALYTICAL CHALLENGES IN TESTING PROCESSES

12 MARKET LANDSCAPE

  • 12.1 MARKET OVERVIEW
  • 12.2 MARKET SIZE & FORECAST
  • 12.3 MARKET OPPORTUNITY
    • 12.3.1 MARKET BY MOLECULE TYPE
    • 12.3.2 MARKET BY THERAPY AREA
    • 12.3.3 MARKET BY MANUFACTURER TYPE
    • 12.3.4 MARKET BY BRAND
    • 12.3.5 MARKET BY POTENCY
    • 12.3.6 MARKET BY GEOGRAPHY
  • 12.4 FIVE FORCES ANALYSIS
    • 12.4.1 THREAT OF NEW ENTRANTS
    • 12.4.2 BARGAINING POWER OF SUPPLIERS
    • 12.4.3 BARGAINING POWER OF BUYERS
    • 12.4.4 THREAT OF SUBSTITUTES
    • 12.4.5 COMPETITIVE RIVALRY

13 MOLECULE TYPE

  • 13.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 13.2 MARKET OVERVIEW
  • 13.3 SMALL MOLECULES/CHEMICAL APIS
    • 13.3.1 MARKET OVERVIEW
    • 13.3.2 MARKET SIZE & FORECAST
    • 13.3.3 SMALL MOLECULES/CHEMICAL APIS BY GEOGRAPHY
  • 13.4 LARGE MOLECULES/BIOLOGICAL APIS
    • 13.4.1 MARKET OVERVIEW
    • 13.4.2 MARKET SIZE & FORECAST
    • 13.4.3 LARGE MOLECULES/BIOLOGICAL APIS BY GEOGRAPHY

14 THERAPY AREA

  • 14.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 14.2 MARKET OVERVIEW
  • 14.3 CARDIOVASCULAR
    • 14.3.1 MARKET OVERVIEW
    • 14.3.2 MARKET SIZE & FORECAST
    • 14.3.3 CARDIOVASCULAR BY GEOGRAPHY
  • 14.4 ONCOLOGY
    • 14.4.1 MARKET OVERVIEW
    • 14.4.2 MARKET SIZE & FORECAST
    • 14.4.3 ONCOLOGY BY GEOGRAPHY
  • 14.5 NEUROLOGY
    • 14.5.1 MARKET OVERVIEW
    • 14.5.2 MARKET SIZE & FORECAST
    • 14.5.3 NEUROLOGY BY GEOGRAPHY
  • 14.6 ANTI-INFECTIVES
    • 14.6.1 MARKET OVERVIEW
    • 14.6.2 MARKET SIZE & FORECAST
    • 14.6.3 ANTI-INFECTIVES BY GEOGRAPHY
  • 14.7 ENDOCRINOLOGY
    • 14.7.1 MARKET OVERVIEW
    • 14.7.2 MARKET SIZE & FORECAST
    • 14.7.3 ENDOCRINOLOGY BY GEOGRAPHY
  • 14.8 PULMONOLOGY
    • 14.8.1 MARKET OVERVIEW
    • 14.8.2 MARKET SIZE & FORECAST
    • 14.8.3 PULMONOLOGY BY GEOGRAPHY
  • 14.9 OTHER THERAPY AREAS
    • 14.9.1 MARKET OVERVIEW
    • 14.9.2 MARKET SIZE & FORECAST
    • 14.9.3 OTHER THERAPY AREAS BY GEOGRAPHY

15 MANUFACTURER TYPE

  • 15.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 15.2 MARKET OVERVIEW
  • 15.3 CAPTIVE
    • 15.3.1 MARKET OVERVIEW
    • 15.3.2 MARKET SIZE & FORECAST
    • 15.3.3 CAPTIVE BY GEOGRAPHY
  • 15.4 MERCHANT
    • 15.4.1 MARKET OVERVIEW
    • 15.4.2 MARKET SIZE & FORECAST
    • 15.4.3 MERCHANT BY GEOGRAPHY

16 BRAND

  • 16.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 16.2 MARKET OVERVIEW
  • 16.3 PATENTED/INNOVATIVE APIS
    • 16.3.1 MARKET OVERVIEW
    • 16.3.2 MARKET SIZE & FORECAST
    • 16.3.3 PATENTED/INNOVATIVE APIS BY GEOGRAPHY
  • 16.4 GENERIC APIS
    • 16.4.1 MARKET OVERVIEW
    • 16.4.2 MARKET SIZE & FORECAST
    • 16.4.3 GENERIC APIS BY GEOGRAPHY

17 POTENCY

  • 17.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 17.2 MARKET OVERVIEW
  • 17.3 NON-POTENT APIS
    • 17.3.1 MARKET OVERVIEW
    • 17.3.2 MARKET SIZE & FORECAST
    • 17.3.3 NON-POTENT APIS BY GEOGRAPHY
  • 17.4 HIGHLY POTENT APIS
    • 17.4.1 MARKET OVERVIEW
    • 17.4.2 MARKET SIZE & FORECAST
    • 17.4.3 HIGHLY POTENT APIS BY GEOGRAPHY

18 GEOGRAPHY

  • 18.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 18.2 GEOGRAPHIC OVERVIEW

19 NORTH AMERICA

  • 19.1 MARKET OVERVIEW
  • 19.2 MARKET SIZE & FORECAST
    • 19.2.1 NORTH AMERICA: MARKET BY MOLECULE TYPE
    • 19.2.2 NORTH AMERICA: MARKET BY THERAPY AREA
    • 19.2.3 NORTH AMERICA: MARKET BY MANUFACTURER TYPE
    • 19.2.4 NORTH AMERICA: MARKET BY BRAND
    • 19.2.5 NORTH AMERICA: MARKET BY POTENCY
  • 19.3 KEY COUNTRIES
    • 19.3.1 US: MARKET SIZE & FORECAST
    • 19.3.2 CANADA: MARKET SIZE & FORECAST

20 APAC

  • 20.1 MARKET OVERVIEW
  • 20.2 MARKET SIZE & FORECAST
    • 20.2.1 APAC: MARKET BY MOLECULE TYPE
    • 20.2.2 APAC: MARKET BY THERAPY AREA
    • 20.2.3 APAC: MARKET BY MANUFACTURER TYPE
    • 20.2.4 APAC: MARKET BY BRAND
    • 20.2.5 APAC: MARKET BY POTENCY
  • 20.3 KEY COUNTRIES
    • 20.3.1 CHINA: MARKET SIZE & FORECAST
    • 20.3.2 INDIA: MARKET SIZE & FORECAST
    • 20.3.3 JAPAN: MARKET SIZE & FORECAST
    • 20.3.4 SOUTH KOREA: MARKET SIZE & FORECAST
    • 20.3.5 AUSTRALIA: MARKET SIZE & FORECAST
    • 20.3.6 INDONESIA: MARKET SIZE & FORECAST
    • 20.3.7 SINGAPORE: MARKET SIZE & FORECAST

21 EUROPE

  • 21.1 MARKET OVERVIEW
  • 21.2 MARKET SIZE & FORECAST
    • 21.2.1 EUROPE: MARKET BY MOLECULE TYPE
    • 21.2.2 EUROPE: MARKET BY THERAPY AREA
    • 21.2.3 EUROPE: MARKET BY MANUFACTURER TYPE
    • 21.2.4 EUROPE: MARKET BY BRAND
    • 21.2.5 EUROPE: MARKET BY POTENCY
  • 21.3 KEY COUNTRIES
    • 21.3.1 GERMANY: MARKET SIZE & FORECAST
    • 21.3.2 UK: MARKET SIZE & FORECAST
    • 21.3.3 RUSSIA: MARKET SIZE & FORECAST
    • 21.3.4 FRANCE: MARKET SIZE & FORECAST
    • 21.3.5 SPAIN: MARKET SIZE & FORECAST
    • 21.3.6 ITALY: MARKET SIZE & FORECAST

22 LATIN AMERICA

  • 22.1 MARKET OVERVIEW
  • 22.2 MARKET SIZE & FORECAST
    • 22.2.1 LATIN AMERICA: MARKET BY MOLECULE TYPE
    • 22.2.2 LATIN AMERICA: MARKET BY THERAPY AREA
    • 22.2.3 LATIN AMERICA: MARKET BY MANUFACTURER TYPE
    • 22.2.4 LATIN AMERICA: MARKET BY BRAND
    • 22.2.5 LATIN AMERICA: MARKET BY POTENCY
  • 22.3 KEY COUNTRIES
    • 22.3.1 BRAZIL: MARKET SIZE & FORECAST
    • 22.3.2 MEXICO: MARKET SIZE & FORECAST
    • 22.3.3 ARGENTINA: MARKET SIZE & FORECAST

23 MIDDLE EAST & AFRICA

  • 23.1 MARKET OVERVIEW
  • 23.2 MARKET SIZE & FORECAST
    • 23.2.1 MIDDLE EAST & AFRICA: MARKET BY MOLECULE TYPE
    • 23.2.2 MIDDLE EAST & AFRICA: MARKET BY THERAPY AREA
    • 23.2.3 MIDDLE EAST & AFRICA: MARKET BY MANUFACTURER TYPE
    • 23.2.4 MIDDLE EAST & AFRICA: MARKET BY BRAND
    • 23.2.5 MIDDLE EAST & AFRICA: MARKET BY POTENCY
  • 23.3 KEY COUNTRIES
    • 23.3.1 TURKEY: MARKET SIZE & FORECAST
    • 23.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST
    • 23.3.3 UAE: MARKET SIZE & FORECAST
    • 23.3.4 SOUTH AFRICA: MARKET SIZE & FORECAST

24 COMPETITIVE LANDSCAPE

  • 24.1 COMPETITION OVERVIEW
    • 24.1.1 RECENT KEY ACTIVITIES IN GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  • 24.2 MARKET SHARE ANALYSIS
    • 24.2.1 ABBVIE
    • 24.2.2 BOEHRINGER INGELHEIM
    • 24.2.3 BRISTOL-MYERS SQUIBB COMPANY
    • 24.2.4 CIPLA
    • 24.2.5 ELI LILLY AND COMPANY
    • 24.2.6 GSK
    • 24.2.7 MERCK KGAA
    • 24.2.8 NOVARTIS
    • 24.2.9 PFIZER
    • 24.2.10 SANOFI
    • 24.2.11 SUN PHARMACEUTICAL INDUSTRIES
    • 24.2.12 VIATRIS

25 KEY COMPANY PROFILES

  • 25.1 ABBVIE
    • 25.1.1 BUSINESS OVERVIEW
    • 25.1.2 PRODUCT OFFERINGS
    • 25.1.3 KEY STRATEGIES
    • 25.1.4 KEY STRENGTHS
    • 25.1.5 KEY OPPORTUNITIES
  • 25.2 BOEHRINGER INGELHEIM
    • 25.2.1 BUSINESS OVERVIEW
    • 25.2.2 PRODUCT OFFERINGS
    • 25.2.3 KEY STRATEGIES
    • 25.2.4 KEY STRENGTHS
    • 25.2.5 KEY OPPORTUNITIES
  • 25.3 BRISTOL-MYERS SQUIBB COMPANY
    • 25.3.1 BUSINESS OVERVIEW
    • 25.3.2 PRODUCT OFFERINGS
    • 25.3.3 KEY STRATEGIES
    • 25.3.4 KEY STRENGTHS
    • 25.3.5 KEY OPPORTUNITIES
  • 25.4 CIPLA
    • 25.4.1 BUSINESS OVERVIEW
    • 25.4.2 PRODUCT OFFERINGS
    • 25.4.3 KEY STRATEGIES
    • 25.4.4 KEY STRENGTHS
    • 25.4.5 KEY OPPORTUNITIES
  • 25.5 ELI LILLY AND COMPANY
    • 25.5.1 BUSINESS OVERVIEW
    • 25.5.2 PRODUCT OFFERINGS
    • 25.5.3 KEY STRATEGIES
    • 25.5.4 KEY STRENGTHS
    • 25.5.5 KEY OPPORTUNITIES
  • 25.6 GSK
    • 25.6.1 BUSINESS OVERVIEW
    • 25.6.2 PRODUCT OFFERINGS
    • 25.6.3 KEY STRATEGIES
    • 25.6.4 KEY STRENGTHS
    • 25.6.5 KEY OPPORTUNITIES
  • 25.7 MERCK KGAA
    • 25.7.1 BUSINESS OVERVIEW
    • 25.7.2 PRODUCT OFFERINGS
    • 25.7.3 KEY STRATEGIES
    • 25.7.4 KEY STRENGTHS
    • 25.7.5 KEY OPPORTUNITIES
  • 25.8 NOVARTIS
    • 25.8.1 BUSINESS OVERVIEW
    • 25.8.2 PRODUCT OFFERINGS
    • 25.8.3 KEY STRATEGIES
    • 25.8.4 KEY STRENGTHS
    • 25.8.5 KEY OPPORTUNITIES
  • 25.9 PFIZER
    • 25.9.1 BUSINESS OVERVIEW
    • 25.9.2 PRODUCT OFFERINGS
    • 25.9.3 KEY STRATEGIES
    • 25.9.4 KEY STRENGTHS
    • 25.9.5 KEY OPPORTUNITIES
  • 25.10 SANOFI
    • 25.10.1 BUSINESS OVERVIEW
    • 25.10.2 PRODUCT OFFERINGS
    • 25.10.3 KEY STRATEGIES
    • 25.10.4 KEY STRENGTHS
    • 25.10.5 KEY OPPORTUNITIES
  • 25.11 SUN PHARMACEUTICAL INDUSTRIES
    • 25.11.1 BUSINESS OVERVIEW
    • 25.11.2 PRODUCT OFFERINGS
    • 25.11.3 KEY STRATEGIES
    • 25.11.4 KEY STRENGTHS
    • 25.11.5 KEY OPPORTUNITIES
  • 25.12 VIATRIS
    • 25.12.1 BUSINESS OVERVIEW
    • 25.12.2 PRODUCT OFFERINGS
    • 25.12.3 KEY STRATEGIES
    • 25.12.4 KEY STRENGTHS
    • 25.12.5 KEY OPPORTUNITIES

26 OTHER PROMINENT VENDORS

  • 26.1 ABBOTT
    • 26.1.1 BUSINESS OVERVIEW
    • 26.1.2 KEY HIGHLIGHTS
  • 26.2 ALBEMARLE CORPORATION
    • 26.2.1 BUSINESS OVERVIEW
    • 26.2.2 KEY HIGHLIGHTS
  • 26.3 AMGEN
    • 26.3.1 BUSINESS OVERVIEW
    • 26.3.2 KEY HIGHLIGHTS
  • 26.4 AUROBINDO PHARMA
    • 26.4.1 BUSINESS OVERVIEW
    • 26.4.2 KEY HIGHLIGHTS
  • 26.5 BASF CORPORATION
    • 26.5.1 BUSINESS OVERVIEW
    • 26.5.2 KEY HIGHLIGHTS
  • 26.6 BIOCON
    • 26.6.1 BUSINESS OVERVIEW
    • 26.6.2 KEY HIGHLIGHTS
  • 26.7 DR. REDDY'S LABORATORIES
    • 26.7.1 BUSINESS OVERVIEW
    • 26.7.2 KEY HIGHLIGHTS
  • 26.8 TEVA PHARMACEUTICAL INDUSTRIES
    • 26.8.1 BUSINESS OVERVIEW
    • 26.8.2 KEY HIGHLIGHTS
  • 26.9 F. HOFFMANN-LA ROCHE
    • 26.9.1 BUSINESS OVERVIEW
    • 26.9.2 KEY HIGHLIGHTS
  • 26.10 GLENMARK PHARMACEUTICALS
    • 26.10.1 BUSINESS OVERVIEW
    • 26.10.2 KEY HIGHLIGHTS
  • 26.11 LUPIN
    • 26.11.1 BUSINESS OVERVIEW
    • 26.11.2 KEY HIGHLIGHTS
  • 26.12 SHENZHEN HEPALINK PHARMACEUTICAL GROUP
    • 26.12.1 BUSINESS OVERVIEW
    • 26.12.2 KEY HIGHLIGHTS

27 REPORT SUMMARY

  • 27.1 KEY TAKEAWAYS
  • 27.2 STRATEGIC RECOMMENDATIONS

28 QUANTITATIVE SUMMARY

  • 28.1 MARKET BY MOLECULE TYPE
    • 28.1.1 NORTH AMERICA: MARKET BY MOLECULE TYPE
    • 28.1.2 APAC: MARKET BY MOLECULE TYPE
    • 28.1.3 EUROPE: MARKET BY MOLECULE TYPE
    • 28.1.4 LATIN AMERICA: MARKET BY MOLECULE TYPE
    • 28.1.5 MIDDLE EAST & AFRICA: MARKET BY MOLECULE TYPE
  • 28.2 MARKET BY THERAPY AREA
    • 28.2.1 NORTH AMERICA: MARKET BY THERAPY AREA
    • 28.2.2 APAC: MARKET BY THERAPY AREA
    • 28.2.3 EUROPE: MARKET BY THERAPY AREA
    • 28.2.4 LATIN AMERICA: MARKET BY THERAPY AREA SEGMENTATION
    • 28.2.5 MIDDLE EAST & AFRICA: MARKET BY THERAPY AREA
  • 28.3 MARKET BY MANUFACTURER TYPE
    • 28.3.1 NORTH AMERICA: MARKET BY MANUFACTURER TYPE SEGMENTATION
    • 28.3.2 APAC: MARKET BY MANUFACTURER TYPE
    • 28.3.3 EUROPE: MARKET BY MANUFACTURER TYPE SEGMENTATION
    • 28.3.4 LATIN AMERICA: MARKET BY MANUFACTURER TYPE SEGMENTATION
    • 28.3.5 MIDDLE EAST & AFRICA: MARKET BY MANUFACTURER TYPE
  • 28.4 MARKET BY BRAND
    • 28.4.1 NORTH AMERICA: MARKET BY BRAND
    • 28.4.2 APAC: MARKET BY BRAND
    • 28.4.3 EUROPE: MARKET BY BRAND
    • 28.4.4 LATIN AMERICA: MARKET BY BRAND
    • 28.4.5 MIDDLE EAST & AFRICA: MARKET BY BRAND
  • 28.5 MARKET BY POTENCY
    • 28.5.1 NORTH AMERICA: MARKET BY POTENCY
    • 28.5.2 APAC: MARKET BY POTENCY
    • 28.5.3 EUROPE: MARKET BY POTENCY
    • 28.5.4 LATIN AMERICA: MARKET BY POTENCY SEGMENTATION
    • 28.5.5 MIDDLE EAST & AFRICA: MARKET BY POTENCY
  • 28.6 MARKET BY GEOGRAPHY
    • 28.6.1 SMALL MOLECULES/CHEMICAL APIS BY GEOGRAPHY
    • 28.6.2 LARGE MOLECULES/BIOLOGICAL APIS BY GEOGRAPHY
    • 28.6.3 CARDIOVASCULAR BY GEOGRAPHY
    • 28.6.4 ONCOLOGY BY GEOGRAPHY
    • 28.6.5 NEUROLOGY BY GEOGRAPHY
    • 28.6.6 ANTI-INFECTIVES BY GEOGRAPHY
    • 28.6.7 ENDOCRINOLOGY BY GEOGRAPHY
    • 28.6.8 PULMONOLOGY BY GEOGRAPHY
    • 28.6.9 OTHER THERAPY AREAS BY GEOGRAPHY
    • 28.6.10 CAPTIVE BY GEOGRAPHY
    • 28.6.11 MERCHANT BY GEOGRAPHY
    • 28.6.12 PATENTED/INNOVATIVE APIS BY GEOGRAPHY
    • 28.6.13 GENERIC APIS BY GEOGRAPHY
    • 28.6.14 NON-POTENT APIS BY GEOGRAPHY
    • 28.6.15 HIGHLY POTENT APIS BY GEOGRAPHY

29 APPENDIX

  • 29.1 ABBREVIATIONS